Medications

FDA approves Xdemvy for Demodex blepharitis

The U.S. Food and Drug Administration has approved Xdemvy (lotilaner ophthalmic solution) 0.25 percent for the treatment of Demodex blepharitis, caused by Demodex mites.

Immunology

Potential long-term treatment for asthma found

A possible way to tackle one of the underlying causes of asthma has been developed by researchers from Aston University and Imperial College London. In tests in mice, the researchers were able to virtually eliminate asthmatic ...

Immunology

New research on dust mites and respiratory infections

When asthmatics' respiratory tracts are exposed to dust mites, their immune response becomes less effective, which can lead to a weaker immune system. People who suffer from asthma associated with infection may therefore ...

page 2 from 7